Diagnostic applications of nuclear medicine: Lymphomas

Nicola M. Hughes; Heather A. Jacene; Sree Harsha Tirumani; Richard L. Wahl

doi:10.1007/978-3-031-05494-5_7

Diagnostic applications of nuclear medicine: Lymphomas

Nicola M. Hughes, Heather A. Jacene, Sree Harsha Tirumani, Richard L. Wahl

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [¹⁸F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [¹⁸F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/necrosis in residual masses. Post-therapy [¹⁸F]FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [¹⁸F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in the setting of clinical trials.

Original language	English
Title of host publication	Nuclear Oncology
Subtitle of host publication	From Pathophysiology to Clinical Applications
Publisher	Springer International Publishing
Pages	431-474
Number of pages	44
ISBN (Electronic)	9783031054945
ISBN (Print)	9783031054938
DOIs	https://doi.org/10.1007/978-3-031-05494-5_7
State	Published - Oct 4 2022

Keywords

Hodgkin lymphoma
Lymphoma
Non-Hodgkin lymphoma
PET/CT
[F]FDG

Access to Document

10.1007/978-3-031-05494-5_7

Cite this

@inbook{409591f7668b44dfb9458e36aa9e72cf,

title = "Diagnostic applications of nuclear medicine: Lymphomas",

abstract = "Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/necrosis in residual masses. Post-therapy [18F]FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for {"}risk-adapted therapy{"} in the setting of clinical trials.",

keywords = "Hodgkin lymphoma, Lymphoma, Non-Hodgkin lymphoma, PET/CT, [F]FDG",

author = "Hughes, {Nicola M.} and Jacene, {Heather A.} and Tirumani, {Sree Harsha} and Wahl, {Richard L.}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2022.",

year = "2022",

month = oct,

day = "4",

doi = "10.1007/978-3-031-05494-5_7",

language = "English",

isbn = "9783031054938",

pages = "431--474",

booktitle = "Nuclear Oncology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Diagnostic applications of nuclear medicine

T2 - Lymphomas

AU - Hughes, Nicola M.

AU - Jacene, Heather A.

AU - Tirumani, Sree Harsha

AU - Wahl, Richard L.

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2022.

PY - 2022/10/4

Y1 - 2022/10/4

N2 - Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/necrosis in residual masses. Post-therapy [18F]FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in the setting of clinical trials.

AB - Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/necrosis in residual masses. Post-therapy [18F]FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in the setting of clinical trials.

KW - Hodgkin lymphoma

KW - Lymphoma

KW - Non-Hodgkin lymphoma

KW - PET/CT

KW - [F]FDG

UR - http://www.scopus.com/inward/record.url?scp=85153805569&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-05494-5_7

DO - 10.1007/978-3-031-05494-5_7

M3 - Chapter

AN - SCOPUS:85153805569

SN - 9783031054938

SP - 431

EP - 474

BT - Nuclear Oncology

PB - Springer International Publishing

ER -

Diagnostic applications of nuclear medicine: Lymphomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this